Register kľúčových slov

Register kľúčových slov

akútne srdcové zlyhávanie (1): 23–26

akútny koronárny syndróm (1): 23–26

aliskirén (1): 11–17

antiagregační léčba (2): 68–73

antidiabetiká (1): 18–22

antihypertenzívne lieky (1): 11–17

anti-VEGF (3): 185–188

AT1-blokátory (2): 68–73

aterogénna dyslipidémia (2): 140–145

ateroskleróza (2): 140–145

autonómna neuropatia (2): 108–116

bazálne analógy inzulínu (2): 130–139

cievy (2): 90–97

cílová hodnota krevního tlaku (2): 68–73

časná inzulinová terapie diabetu 2. typu (3): 165–168

časná kombinační léčba (3): 165–168

časná léčba diabetu (3): 165–168

dermoepidermálne štepy (2): 98–101

diabetes mellitus (1): 18–22

(1): 23–26

(1): 27–30

(1): 31–35

(1): 36–40

(2): 102–107

(2): 108–116

(2): 117–121

(3): 190–192

diabetes mellitus 1. typu (3): 185–188

diabetes mellitus 2. typu (2): 122–124

diabetes mellitus-výskyt (3): 193–199

diabetická kardiomyopatia (1): 18–22

diabetická nefropatia (1): 31–35

(2): 117–121

(S1): 1–6

diabetická noha (2): 74–83

(2): 90–97

(2): 98–101

diabetická retinopatia (3): 170–175

(3): 176–180

(3): 181–184

(3): 193–199

diabetické ulcerace (2): 102–107

diabetický edém makuly (3): 170–175

(3): 185–188

(3): 193–199

diagnostika diabetickej nefropatie (2): 117–121

dysliporoteinémia (2): 140–145

endovaskulárne výkony (2): 90–97

etiopatogenéza (2): 84–89

glaukóm (3): 190–192

gliptíny (2): 130–139

gravidita (3): 176–180

(3): 181–184

hypertriacylglycerolémie (2): 140–145

hypolipidemika (2): 68–73

chronická rana (2): 98–101

indikačné obmedzenia (2): 130–139

inhibitory ACE (2): 68–73

intenzifikovaný inzulínový režim (2): 122–124

inzulín lispro mix (2): 122–124

jednoduchosť a finančná nenáročnosť (2): 98–101

kardiorenálny syndróm (1): 31–35

kardiovaskulárne ochorenia (1): 27–30

kardiovaskulární mortalita (2): 102–107

kardiovaskulární riziko (3): 165–168

komorová fibrilácia (1): 36–40

kompliancia (1): 11–17

komplikácie (2): 108–116

larvoterapia (2): 74–83

laserová liečba (3): 176–180

léčba prediabetu (3): 165–168

liečba pomocou živých bunkových línií (2): 74–83

liečba riadeným podtlakom (2): 74–83

mikroalbuminúria (2): 117–121

mikroalbuminurie (2): 68–73

multiorgánovomultivaskulárna choroba (1): 36–40

nefroprotekce (2): 68–73

neovaskularizácie terča zrakového nervu (3): 185–188

neovaskulárny glaukóm (3): 190–192

pars plana vitrektómia (3): 170–175

periférna neuropatia (2): 108–116

podiatrické centrum (2): 102–107

prediabetes (3): 165–168

predsieňová fibrilácia (1): 27–30

premixované inzulínové analógy (2): 122–124

prevence diabetu (3): 165–168

primárny glaukóm s otvoreným uhlom (3): 190–192

ranibizumab (3): 185–188

rehospitalizácie pre akútne ochorenia (1): 23–26

rizikové faktory (2): 84–89

skríning (3): 176–180

srdcové zlyhávanie (1): 18–22

syndróm diabetickej nohy (2): 84–89

tehotenstvo (3): 181–184

tlak vnutroočný (3): 190–192

tolerancia (1): 11–17

transplantácia autológnych štepov (2): 98–101

trvanie účinku (1): 11–17

zobrazovacie metódy (2): 90–97

Index of key words

key word (číslo): strany

key word (číslo): strany

ACE inhibitors (2): 68–73

acute coronary syndrome (1): 23–26

acute heart failure (1): 23–26

aliskiren (1): 11–17

angiotensin receptor blockers (2): 68–73

antidiabetics (1): 18–22

antihypertensive drugs (1): 11–17

antiplatelet therapy (2): 68–73

anti-VEGF (3): 185–188

atherogenic dyslipidemia (2): 140–145

atherosclerosis (2): 140–145

atrial fibrilation (1): 27–30

autonomic neuropathy (2): 108–116

basal insulin analogues (2): 130–139

blood vessels (2): 90–97

cardiorenal syndrome (1): 31–35

cardiovascular disease (1): 27–30

cardiovascular mortality (2): 102–107

cardiovascular risk (3): 165–168

compliance (1): 11–17

complications (2): 108–116

dermoepidermal skin grafts (2): 98–101

diabetes mellitus (1): 18–22

(1): 23–26

(1): 27–30

(1): 31–35

(1): 36–40

(2): 102–107

(2): 108–116

(2): 117–121

(3): 190–192

diabetes mellitus type 1  (3): 185–188

diabetes mellitus type 2 (2): 122–124

diabetes mellitus-incidence (3): 193–199

diabetes prevention (3): 165–168

diabetic cardiomyopathy (1): 18–22

diabetic foot (2): 74–83

(2): 90–97

(2): 98–101

diabetic foot clinic (2): 102–107

diabetic foot syndrome (2): 84–89

diabetic foot ulcer (2): 102–107

diabetic macular edema (3): 170–175

(3): 185–188

(3): 193–199

diabetic nephropathy (1): 31–35

(2): 117–121

(S1): 1–6

diabetic retinopathy (3): 170–175

(3): 176–180

(3): 181–184

(3): 193–199

diagnosis of diabetic nephropathy (2): 117–121

duration of action (1): 11–17

dyslipoproteinemia (2): 140–145

early combination treatment (3): 165–168

early insulin treatment in type 2 diabetes (3): 165–168

early treatment of diabetes (3): 165–168

endovascular intervention (2): 90–97

etiopathogenesis (2): 84–89

forgiveness (1): 11–17

glaucoma (3): 190–192

gliptines (2): 130–139

goal blood pressure (2): 68–73

heart failure (1): 18–22

hypertriglyceridemia (2): 140–145

chronical wound (2): 98–101

imaging methods (2): 90–97

indicating restrictions (2): 130–139

insulin lispro mix (2): 122–124

intensified insulin regimen (2): 122–124

intraocular pressure (3): 190–192

laser treatment (3): 176–180

lipid-lowering drugs (2): 68–73

maggot therapy (2): 74–83

microalbuminuria (2): 68–73

(2): 117–121

multiorganomultivascular arterial disease (1): 36–40

neovascular glaucoma (3): 190–192

nephroprotection (2): 68–73

optic disc neovascularization (3): 185–188

pars plana vitrektómia (3): 170–175

peripheral neuropathy (2): 108–116

prediabetes (3): 165–168

prediabetes treatment (3): 165–168

pregnancy (3): 176–180

(3): 181–184

premixed insulin analogues (2): 122–124

primary open-angle glaucoma POAG (3): 190–192

ranibizumab (3): 185–188

rehospitalization for acute diseases (1): 23–26

risk factors (2): 84–89

screening (3): 176–180

simplicity and low cost (2): 98–101

transplatation of autolog skin grafts (2): 98–101

treatment with controlled vacuum (2): 74–83

treatment with live cell lines (2): 74–83

ventricular fibrilation (1): 36–40